Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

1. 60-day major adverse cardiac events in emergency department patients with non-low modified HEART scores

60-day major adverse cardiac events in emergency department patients with non-low modified HEART scores 60-day major adverse cardiac events in emergency department patients with non-low modified HEART scores - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center (...) Copy Actions Cite Share Permalink Copy Page navigation Case Reports Am J Emerg Med Actions . 2020 May 28;S0735-6757(20)30442-3. doi: 10.1016/j.ajem.2020.05.081. Online ahead of print. 60-day major adverse cardiac events in emergency department patients with non-low modified HEART scores , , , , , , Affiliations Expand Affiliations 1 Department of Emergency Medicine, Kaiser Permanente, 3600 Broadway, Oakland, CA 94611, USA; Department of Critical Care Medicine, Kaiser Permanente, 3600 Broadway

2020 EvidenceUpdates

2. Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project

Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Haemost Actions . 2020 Jun 7. doi: 10.1055/s-0040-1712914. Online ahead of print. Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project # , # , , , , Affiliations Expand Affiliations 1 Department of Cardiology, Hospital Clínico

2020 EvidenceUpdates

3. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis

Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Rheumatology (Oxford) Actions . 2020 May 14;keaa117. doi: 10.1093/rheumatology/keaa117. Online ahead of print. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis , , , , Affiliations Expand Affiliations 1 Department of Respiratory Medicine, Alfred Hospital. 2 Central Clinical School, Monash University, Melbourne. 3 Cabrini Medical Centre

2020 EvidenceUpdates

4. Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis

Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National (...) of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Haemost Actions . 2020 May;120(5):866-875. doi: 10.1055/s-0040-1709711. Epub 2020 May 5. Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis , , , , , , Affiliations Expand Affiliations 1 Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Italy. 2 Department

2020 EvidenceUpdates

5. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors Full Text available with Trip Pro

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors EULAR Points to Consider for the Diagnosis and Management of Rheumatic Immune-Related Adverse Events Due to Cancer Immunotherapy With Checkpoint Inhibitors - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Ann Rheum Dis Actions . 2020 Apr 23;annrheumdis-2020-217139. doi: 10.1136/annrheumdis-2020-217139. Online ahead of print. EULAR Points to Consider for the Diagnosis and Management of Rheumatic Immune-Related Adverse Events Due to Cancer Immunotherapy With Checkpoint Inhibitors , , , , , , , , , , , , , , , , , , , , , , Affiliations

2020 EvidenceUpdates

6. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. (Abstract)

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis. Pooled phase 2 data suggest (...) favorable effects on clinical outcomes.To test whether apabetalone significantly reduces major adverse cardiovascular events.A randomized, double-blind, placebo-controlled trial, conducted at 190 sites in 13 countries. Patients with an acute coronary syndrome in the preceding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligible for enrollment, which started November 11, 2015, and ended July 4, 2018, with end of follow-up on July 3, 2019.Patients were

2020 JAMA

7. Impact of Timing of Preprocedural Opioids on Adverse Events in Procedural Sedation (Abstract)

Impact of Timing of Preprocedural Opioids on Adverse Events in Procedural Sedation The risk of respiratory depression is increased when opioids are added to sedative agents. In our recent multicenter emergency department (ED) procedural sedation cohort, we reported a strong association between preprocedural opioids and sedation-related adverse events. We sought to examine the association between timing of opioids and the incidence of adverse sedation outcomes.We conducted a secondary analysis

2020 EvidenceUpdates

8. ASGE review of adverse events in colonoscopy

ASGE review of adverse events in colonoscopy ASGE STANDARDS OF PRACTICE COMMITTEE REVIEW ASGE review of adverse events in colonoscopy Shivangi T. Kothari, MD, FASGE, 1, * Robert J. Huang, MD, 2, * Aasma Shaukat, MD, MPH, FASGE, 3 Deepak Agrawal, MD, FASGE, 4 James L. Buxbaum, MD, FASGE, 5 Syed M. Abbas Fehmi, MD, MSc, FASGE, 6 Douglas S. Fishman, MD, FASGE, 7 Suryakanth R. Gurudu, MD, FASGE, 8 Mouen A. Khashab, MD, 9 Laith H. Jamil, MD, FASGE, 10 Terry L. Jue, MD, FASGE, 11 Joanna K. Law, MD (...) - cedure. However, adverse events (AEs) related to this routinely performed procedure for screening, diagnostic, ortherapeuticpurposesareanimportantclinicalconsideration.ThepurposeofthisdocumentfromtheAmerican Society for Gastrointestinal Endoscopy’s Standards of Practice Committee is to provide an update on estimates of AEs related to colonoscopy in an evidence-based fashion. A systematic review and meta-analysis of population- based studies was conducted for the 3 most common and important serious

2020 American Society for Gastrointestinal Endoscopy

9. ERCP-related adverse events

ERCP-related adverse events ERCP-relatedadverseevents:EuropeanSocietyofGastrointestinal Endoscopy (ESGE) Guideline Authors Jean-MarcDumonceau 1 ,ChristineKapral 2 ,Lars Aabakken 3 ,IoannisS.Papanikolaou 4 ,Andrea Tringali 5,6 ,Geoffroy Vanbiervliet 7 ,Torsten Beyna 8 ,MarioDinis-Ribeiro 9,10 ,IstvanHritz 11 ,AlbertoMariani 12 ,Gregorios Paspatis 13 ,Franco Radaelli 14 , SundeepLakhtakia 15 ,AndrewM.Veitch 16 ,JeaninE.vanHooft 17 Institutions ?1 Gastroenterology Service, Hôpital Civil Marie (...) viewableat: https://doi.org/10.1055/a-1075-4080 Dumonceau Jean-Marc et al. ERCP-related adverse events: ESGEClinical Guideline… Endoscopy1Introduction The range and incidence of adverse events (AEs) related to endoscopic retrograde cholangiopancreatography (ERCP) dif- fer substantially from those related to other endoscopic proce- dures. Familiarity with these AEs is critical for providing patient information during the consent phaseas well as for prophylaxis and management. Adverse events related

2020 European Society of Gastrointestinal Endoscopy

10. Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial Full Text available with Trip Pro

Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial Safety and Adverse Events After Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) to Collections Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Am J Respir Crit Care Med Actions , 200 (12), 1477-1486 2019 Dec 15 Safety and Adverse Events After Targeted Lung Denervation for Symptomatic Moderate

2020 EvidenceUpdates

11. During Conscious Sedation the Risk of Adverse Events Is Likely Increased in Obese Children Compared to Those of Healthy Weight

During Conscious Sedation the Risk of Adverse Events Is Likely Increased in Obese Children Compared to Those of Healthy Weight UTCAT3394, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title During Conscious Sedation the Risk of Adverse Events Is Likely Increased in Obese Children Compared to Those of Healthy Weight Clinical Question Are obese children undergoing conscious sedation at increased risk for adverse events (...) compared to children who are at healthy weight? Clinical Bottom Line For children with childhood obesity, conscious sedation may lead to more adverse events including oxyhemoglobin desaturation, nausea and true apnea. However, additional evidence is needed to know if there is any clinical and statistical difference between obese children and healthy weight children during conscious sedation. This is supported by both a cross-sectional retrospective study and a review of literature on the relationship

2019 UTHSCSA Dental School CAT Library

12. Performance of cardiac troponins within the HEART score in predicting major adverse cardiac events at the emergency department (Abstract)

Performance of cardiac troponins within the HEART score in predicting major adverse cardiac events at the emergency department This study compared the performance of a single blood draw of high-sensitivity troponin T (hsTnT), high-sensitivity troponin I (hsTnI) and conventional troponin I (cTnI) within a modified HEART score for predicting 30-day MACE at Emergency Department (ED) presentation, and established local reference norms for all three assays by determining the cut-off point which

2019 EvidenceUpdates

13. Predicting Major Adverse Events in Patients With Acute Myocardial Infarction (Abstract)

Predicting Major Adverse Events in Patients With Acute Myocardial Infarction Early and accurate detection of short-term major adverse cardiac events (MACE) in patients with suspected acute myocardial infarction (AMI) is an unmet clinical need.The goal of this study was to test the hypothesis that adding clinical judgment and electrocardiogram findings to the European Society of Cardiology (ESC) high-sensitivity cardiac troponin (hs-cTn) measurement at presentation and after 1 h (ESC hs-cTn 0/1 (...)  h algorithm) would further improve its performance to predict MACE.Patients presenting to an emergency department with suspected AMI were enrolled in a prospective, multicenter diagnostic study. The primary endpoint was MACE, including all-cause death, cardiac arrest, AMI, cardiogenic shock, sustained ventricular arrhythmia, and high-grade atrioventricular block within 30 days including index events. The secondary endpoint was MACE + unstable angina (UA) receiving early (≤24 h

2019 EvidenceUpdates

14. Inhaled steroids with and without regular formoterol for asthma: serious adverse events. (Abstract)

Inhaled steroids with and without regular formoterol for asthma: serious adverse events. Epidemiological evidence has suggested a link between beta2-agonists and increases in asthma mortality. There has been much debate about whether regular (daily) long-acting beta2-agonists (LABA) are safe when used in combination with inhaled corticosteroids (ICS). This updated Cochrane Review includes results from two large trials that recruited 23,422 adolescents and adults mandated by the US Food and Drug (...) Administration (FDA).To assess the risk of mortality and non-fatal serious adverse events (SAEs) in trials that randomly assign participants with chronic asthma to regular formoterol and inhaled corticosteroids versus the same dose of inhaled corticosteroid alone.We identified randomised trials using the Cochrane Airways Group Specialised Register of trials. We checked websites of clinical trial registers for unpublished trial data as well as FDA submissions in relation to formoterol. The date of the most

2019 Cochrane

15. Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function. (Abstract)

Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function. Before 2016, safety concerns limited metformin use in patients with kidney disease; however, the effectiveness of metformin on clinical outcomes in patients with reduced kidney function remains unknown.To compare major adverse cardiovascular events (MACE) among patients with diabetes and reduced kidney function who continued treatment (...) of 6.6% [IQR, 6.1%-7.2%] at cohort entry). During follow-up (median, 1.0 year for metformin vs 1.2 years for sulfonylurea), there were 1048 MACE outcomes (23.0 per 1000 person-years) among metformin users and 1394 events (29.2 per 1000 person-years) among sulfonylurea users. The cause-specific adjusted hazard ratio of MACE for metformin was 0.80 (95% CI, 0.75-0.86) compared with sulfonylureas, yielding an adjusted rate difference of 5.8 (95% CI, 4.1-7.3) fewer events per 1000 person-years

2019 JAMA

16. Planning to reduce 30-day adverse events after discharge of frail elderly patients with acute heart failure: design and rationale for the DEED FRAIL-AHF trial. (Abstract)

Planning to reduce 30-day adverse events after discharge of frail elderly patients with acute heart failure: design and rationale for the DEED FRAIL-AHF trial. To demonstrate the efficacy of a system for comprehensive care transfer (Multilevel Guided Discharge Plan [MGDP]) for frail older patients diagnosed with acute heart failure (AHF) and to validate the results of MGDP implementation under real clinical conditions. The MGDP seeks to reduce the number of adverse outcomes within 30 days

2019 Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias Controlled trial quality: uncertain

17. Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study. (Abstract)

Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study. Randomized trials demonstrate no benefit from antibiotic treatment exceeding the shortest effective duration.To examine predictors and outcomes associated with excess duration of antibiotic treatment.Retrospective cohort study.43 hospitals in the Michigan Hospital Medicine Safety Consortium.6481 general care medical patients with pneumonia.The primary outcome (...) , or did not have a total antibiotic treatment duration documented at discharge were more likely to receive excess treatment. Excess treatment was not associated with lower rates of any adverse outcomes, including death, readmission, emergency department visit, or Clostridioides difficile infection. Each excess day of treatment was associated with a 5% increase in the odds of antibiotic-associated adverse events reported by patients after discharge.Retrospective design; not all patients could

2019 Annals of Internal Medicine

18. Effect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial (Abstract)

Effect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial Tonsillectomy is a common pediatric procedure for the treatment of sleep-disordered breathing and chronic tonsillitis. Up to half of children having this procedure experience a perioperative respiratory adverse event.To determine whether inhaled albuterol sulfate (salbutamol sulfate) premedication decreases the risk (...) of perioperative respiratory adverse events in children undergoing anesthesia for tonsillectomy.A randomized, triple-blind, placebo-controlled trial (the Reducing Anesthetic Complications in Children Undergoing Tonsillectomies [REACT] trial) was conducted at Perth Children's Hospital (formerly Princess Margaret Hospital for Children), the only tertiary pediatric hospital in Western Australia. Participants included 484 children aged 0 to 8 years who were undergoing anesthesia for tonsillectomy. The study

2019 EvidenceUpdates

19. What Is the Diagnostic Accuracy of Cardiac Biomarkers for the Prediction of Adverse Cardiac Events in Patients Presenting With Acute Syncope? Full Text available with Trip Pro

What Is the Diagnostic Accuracy of Cardiac Biomarkers for the Prediction of Adverse Cardiac Events in Patients Presenting With Acute Syncope? What Is the Diagnostic Accuracy of Cardiac Biomarkers for the Prediction of Adverse Cardiac Events in Patients Presenting With Acute Syncope? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 73, Issue 5, Pages 511–513 What Is the Diagnostic Accuracy of Cardiac (...) Biomarkers for the Prediction of Adverse Cardiac Events in Patients Presenting With Acute Syncope? x Jason R. West , MD (EBEM Commentator) , x James Russell , MD (EBEM Commentator) Department of Emergency Medicine, Lincoln Medical and Mental Health Center, Bronx, NY DOI: | Publication History Published online: August 27, 2018 Expand all Collapse all Article Outline Take-Home Message The sensitivity of brain-type natriuretic peptides and troponin for identifying syncopal patients at risk for major cardiac

2019 Annals of Emergency Medicine Systematic Review Snapshots

20. Serious adverse events and lifetime risk of reoperation after elective shoulder replacement: population based cohort study using hospital episode statistics for England. Full Text available with Trip Pro

Serious adverse events and lifetime risk of reoperation after elective shoulder replacement: population based cohort study using hospital episode statistics for England. To provide accurate risk estimates of serious adverse events after elective shoulder replacement surgery for arthritis, including age and sex specific estimates of the lifetime risk of revision surgery.Population based cohort study.Hospital episode statistics for NHS England, including civil registration mortality data.58 054 (...) elective shoulder replacements in 51 895 adults (aged ≥50 years) between April 1998 and April 2017.The lifetime risk of revision surgery, calculated using an actuarial life table approach and the cumulative probability method. Rates of serious adverse events at 30 and 90 days post-surgery: pulmonary embolism, myocardial infarction, lower respiratory tract infection, acute kidney injury, urinary tract infection, cerebrovascular events, and all cause death. Secondary outcome measures were the number

2019 BMJ